How will we vote? Outbreak revives debate mail-in ballots    Poland vote could be postponed if safety not guaranteed: President    What you need to know about the Central Bank of Egypt's new cash deposits and daily withdrawal limits    Great time for long-term investors to put money into US: Mnuchin    Saudi, UAE businesses battle cash crunch despite anti-coronavirus stimulus    Tokyo Olympics rescheduled for July 23-Aug 2021: Organizing committee    Iran's coronavirus death toll reaches 2,757: Health official    Serie A hits back at Italy sports minister Spadafora over 'bubble' remark    Drop in China's new coronavirus cases; none in Wuhan for sixth day    How coronavirus affects real estate market in Santa Clarita Valley    Egypt's FRA launches policies for micro-finance activity amid coronavirus    Mourinho to take Tottenham training via video amid coronavirus lockdown    Egypt's defender Elmohamady proud of 10-year milestone in England    Coronavirus to drive decline in home prices, more rent freezes in Dubai    Facebook users add ‘Stay At Home' frame to profile photos    UK epidemic is slowing and antibody test could be ready in days, top epidemiologist says    Twitter removes 2 Bolsonaro tweets questioning coronavirus quarantine    Egypt to extend closing mosques over coronavirus fears – minister    El-Tayeb urges Egyptians to stick to coronavirus preventative measures    Egypt, MENA growth forecast at 2.7%, -0.3% respectively: IIF    Prosecution warns of EGP 300k fine or 2-year jail for spreading fake coronavirus news    Al-Sisi discusses joint coronavirus efforts with Abu Dhabi Crown Prince    Saudi Arabia intercepts missiles over Riyadh    CBE temporarily regulates cash deposits, withdrawals    Lagging COVID-19 response to shield frail economy: Rouhani    Saudi Arabia shuts entry and exit into Jeddah, brings forward curfew - state news agency    Apple works with US House to release coronavirus app, website    California's houisng market unclear after new restrictions amid coronavirus    Farwell to Egyptian comedian George Sidhom    Weekend's virtual concerts, plays, and festivals people can stream at home    Egyptian comedy icon George Sidhom dies at 81    Shooting Egypt's Ramadan television series in the time of coronavirus    Egyptian court sentences five to death for vandalising gas pipeline, killing nine    Amid coronavirus outbreak, Egyptian Premier League cancellation seems inevitable    Brazilian football stadiums transformed into hospitals to treat coronavirus patients    Stay At Home: Ministry of Culture to publish free books online for public browsing    ‘We are here to boost the morale': Ahmed Zeidan, Egypt's ROOM Art Space& Café    IOC postpones Tokyo Olympics due to coronavirus pandemic    Playing for time    Water effects of the dam    What to watch to kill time in quarantine?    Japan PM Abe agree on delaying the Tokyo Olympics for one year    Ethiopia has not sent Egypt latest designs for GERD: Minister of Irrigation    Al-Sisi appreciates Kenya's support to Egypt's stance on GERD    Nigerien President hails Egypt's diplomatic attempts to reach agreement over GERD    Tom Hanks and wife Rita Wilson announced both test positive for coronavirus    Cairo court acquits Mubarak's sons of stock market manipulation    Egypt's President Sisi pardons some prisoners on 25 Jan. Revolution anniversary    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Ebola “no longer incurable” as Congo trial finds drugs 90% survival rates
Published in Amwal Al Ghad on 14 - 08 - 2019

Scientists are a step closer to being able to cure the deadly Ebola haemorrhagic fever as two experimental drugs showed survival rates of more than 90 percent in a clinical trial in Congo.
Two experimental drugs – an antibody cocktail named REGN-EB3 developed by Regeneron and a monoclonal antibody called mAb114 – will now be offered to all patients infected with the viral disease in an ongoing outbreak in the Democratic Republic of Congo (DRC).
The drugs showed "clearly better" results, according to the U.S. National Institute of Allergy and Infectious Diseases (NIAID), in a trial of four potential treatments being conducted during the second-largest Ebola outbreak in history, now entering its second year in DRC.
The drugs improved survival rates from the disease more than two other treatments being tested – ZMapp, made by Mapp Biopharmaceutical, and Remdesivir, made by Gilead Sciences – and those products will be now dropped, said Anthony Fauci, one of the researchers co-leading the trial.
The agency said 49 percent of the patients on ZMapp and 53 percent on Remdesivir died in the study. In comparison, 29 percent of the patients on REGN-EB3 and 34 percent on mAb114 died.
Jean-Jacques Muyembe, director general of Congo's Institut National de Recherche Biomédicale in DRC, who co-led the trial, said the results meant that "from now on, we will no longer say that Ebola is incurable."
"These advances will help save thousands of lives," he told reporters.
Anthony Fauci, NIAID's director, also said the results were "very good news" for the fight against Ebola.
The agency said that of the patients who were brought into treatment centres with low levels of virus detected in their blood, 94 percent who got REGN-EB3 and 89 percent on mAb114 survived.
In comparison, two-thirds of the patients who got Remdesivir and nearly three-quarters on ZMapp survived.
Ebola has been spreading in eastern Congo since August 2018 in an outbreak that has now killed at least 1,800 people. Efforts to control it have been hampered by militia violence and some local resistance to outside help.
A vast Ebola outbreak in West Africa from 2013 to 2016 became the world's largest ever when it spread through Guinea, Liberia and Sierra Leone and killed more than 11,300 people.
The Congo treatment trial, which began in November last year, is being carried out by an international research group coordinated by the World Health Organization (WHO).
Mike Ryan, head of the WHO's emergencies program, said the trial's positive findings were encouraging but would not be enough on their own to bring the epidemic to an end.
"The news today is fantastic. It gives us a new tool in our toolbox against Ebola, but it will not in itself stop Ebola," he told reporters.
Jeremy Farrar, director of the Wellcome Trust global health charity, also hailed the success of the trial's findings, saying they would "undoubtedly save lives".
"The more we learn about these two treatments … the closer we can get to turning Ebola from a terrifying disease to one that is preventable and treatable," he said in a statement.
"We won't ever get rid of Ebola but we should be able to stop these outbreaks from turning into major national and regional epidemics."
Some 681 patients at four separate treatment centres in Congo have already been enrolled in the Congo treatment clinical trial, Fauci said. The study aims to enrol a total of 725.
The decision to drop two of the trial drugs was based on data from almost 500 patients, he said, which showed that those who got REGN-EB3 or mAb114 "had a greater chance of survival compared to those participants in the other two arms".
The two promising drugs are made from Ebola antibodies – a protein produced by the immune system to defend against infection. Regeneron's product is a cocktail of three Ebola antibodies, while mAb114 is a single antibody developed by scientists at NIAID.
Source: Reuters


Clic here to read the story from its source.